Metastatic uveal melanoma commonly spreads to the liver, and percutaneous hepatic perfusion can help control tumors within ...

HealthDay News — For patients with asthma, receipt of immune checkpoint inhibitor (ICI) therapy for melanoma or renal cell carcinoma is not associated with an increased risk for exacerbations, ...

A groundbreaking study from Tata Memorial Hospital shows that using ultra-low doses of nivolumab, an immunotherapy drug, can effectively treat cancer while drastically reducing costs by 90%. This ...

Breakthrough immunotherapy trials are showing unprecedented responses in a subset of rectal cancer patients, hinting at a ...

In Perioperative Immunotherapy Advances: Insights from CheckMate-77T and KEYNOTE-671, our panel delves into the following ...

During a live event, Daniel Olson, MD, discussed data and experience using tumor-infiltrating lymphocytes in melanoma.

Induction Yervoy (ipilimumab) plus Opdivo (nivolumab) followed by consolidative chemoradiotherapy demonstrated bladder ...

Replimune’s RP1+nivolumab melanoma BLA faces an FDA decision by Apr 10, 2026. The current cash runway extends to Q1'27. See more on REPL stock here.

Pharmac currently funds pembrolizumab, for people with melanoma which can be removed by surgery. Funding nivolumab combined with ipilimumab would mean that some patients would require fewer infusions, ...

Predictable reimbursement is a primary operational determinant of biosimilar longevity in practices, frequently outweighing ...

Consultation's open on whether to expand access to two immunotherapy medicines for people with stage 3b and 4 melanoma from May. Used pre-surgery, nivolumab and ipilimumab can lower the chance of ...

Telix reported FY2025 revenue of $804M, up 56% YoY, with Precision Portfolio products Illuccix and Gozellix contributing $622M. Read why TLX stock is a Buy.